

PUBLICATIONS (updated 2/22/12)

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. **Carpenter LL**, Kupfer DJ, Frank E. 1986. Is diurnal variation a meaningful symptom in unipolar depression? *J Affect Disord* 11(3):255-64.
2. Jacob M, Frank E, Kupfer DJ, **Carpenter LL**. 1987. Recurrent depression: an assessment of family burden and family attitudes. *J Clin Psychiatry* 48(10):395-400.
3. Jacob M, Frank E, Kupfer DJ, Cornes C, **Carpenter LL**. 1987. A psychoeducational workshop for depressed patients, family, and friends: description and evaluation. *Hosp Community Psychiatry* 38(9):968-72.
4. Frank E, **Carpenter LL**, Kupfer DJ. 1988. Sex differences in recurrent depression: are there any that are significant? *Am J Psychiatry* 145(1):41-5.
5. Kupfer DJ, **Carpenter LL**, Frank E. 1988a. Possible role of antidepressants in precipitating mania and hypomania in recurrent depression. *Am J Psychiatry* 145(7):804-8.
6. Kupfer DJ, **Carpenter LL**, Frank E. 1988b. Is bipolar II a unique disorder? *Compr Psychiatry* 29(3):228-36.
7. Kupfer DJ, Frank E, **Carpenter LL**, Neiswanger K. 1989. Family history in recurrent depression. *J Affect Disord* 17(2):113-9.
8. Bulik CM, **Carpenter LL**, Kupfer DJ, Frank E. 1990. Features associated with suicide attempts in recurrent major depression. *J Affect Disord* 18(1):29-37.
9. Prien RF, **Carpenter LL**, Kupfer DJ. 1991. The definition and operational criteria for treatment outcome of major depressive disorder. A review of the current research literature. *Arch Gen Psychiatry* 48(9):796-800.
10. Thase ME, **Carpenter L**, Kupfer DJ, Frank E. 1991. Clinical significance of reversed vegetative subtypes of recurrent major depression. *Psychopharmacol Bull* 27(1):17-22.
11. **Carpenter LL**, McDougle CJ, Epperson CN, Price LH. 1996. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. *Drug Saf* 15(2):116-34.
12. Platis IE, **Carpenter LL**, Vojvoda D, Bowers MB, Jr., Mazure CM. 1996. Possible acceleration of alcoholic cirrhosis in a patient with bulimia. *Int J Eat Disord* 20(4):439-42.
13. **Carpenter LL**, Anderson GM, Pelton GH, Gudín JA, Kirwin PD, Price LH, Heninger GR, McDougle CJ. 1998. Tryptophan depletion during continuous CSF sampling in healthy human subjects. *Neuropsychopharmacology* 19(1):26-35.
14. Malison RT, McCance E, **Carpenter LL**, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB. 1998. [¹²³I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts. *Psychopharmacology (Berl)* 137(4):321-5.
15. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, **Carpenter L**, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS. 1998. Reduced

brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropine and single photon emission computed tomography. *Biol Psychiatry* 44(11):1090-8.

16. **Carpenter LL**, Jovic Z, Hall JM, Rasmussen SA, Price LH. 1999. Mirtazapine augmentation in the treatment of refractory depression. *J Clin Psychiatry* 60(1):45-9.
17. **Carpenter LL**, Leon Z, Yasmin S, Price LH. 1999. Clinical experience with mirtazapine in the treatment of panic disorder. *Ann Clin Psychiatry* 11(2):81-6.
18. Longhurst JG, **Carpenter LL**, Epperson CN, Price LH, McDougle CJ. 1999. Effects of catecholamine depletion with AMPT (alpha-methyl-para-tyrosine) in obsessive-compulsive disorder. *Biol Psychiatry* 46(4):573-6.
19. Malison RT, Anand A, Pelton GH, Kirwin P, **Carpenter L**, McDougle CJ, Heninger GR, Price LH. 1999. Limited efficacy of ketoconazole in treatment-refractory major depression. *J Clin Psychopharmacol* 19(5):466-70.
20. **Carpenter LL**, Price LH. 2000. Psychotic depression: what is it and how should we treat it? *Harv Rev Psychiatry* 8(1):40-2.
21. Gagne GG, Jr., Furman MJ, **Carpenter LL**, Price LH. 2000. Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. *Am J Psychiatry* 157(12):1960-5.
22. Vythilingam M, Anderson GM, Owens MJ, Halaszynski TM, Bremner JD, **Carpenter LL**, Heninger GR, Nemeroff CB, Charney DS. 2000. Cerebrospinal fluid corticotropin-releasing hormone in healthy humans: effects of yohimbine and naloxone. *J Clin Endocrinol Metab* 85(11):4138-45.
23. Yasmin S, **Carpenter LL**, Leon Z, Siniscalchi JM, Price LH. 2001. Adjunctive gabapentin in treatment-resistant depression: a retrospective chart review. *J Affect Disord* 63(1-3):243-7.
24. **Carpenter LL**, Heninger GR, McDougle CJ, Tyrka AR, Epperson CN, Price LH. 2002. Cerebrospinal fluid interleukin-6 in obsessive-compulsive disorder and trichotillomania. *Psychiatry Res* 112(3):257-62.
25. **Carpenter LL**, Leon Z, Yasmin S, Price LH. 2002. Do obese depressed patients respond to topiramate? A retrospective chart review. *J Affect Disord* 69(1-3):251-5.
26. **Carpenter LL**, Yasmin S, Price LH. 2002. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. *Biol Psychiatry* 51(2):183-8.
27. Cubells JF, Price LH, Meyers BS, Anderson GM, Zabetian CP, Alexopoulos GS, Nelson JC, Sanacora G, Kirwin P, **Carpenter L**, Malison RT, Gelernter J. 2002. Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression. *Biol Psychiatry* 51(5):358-64.
28. **Carpenter LL**, Anderson GM, Siniscalchi JM, Chappell PB, Price LH. 2003. Acute changes in cerebrospinal fluid 5-HIAA following oral paroxetine challenge in healthy humans. *Neuropsychopharmacology* 28(2):339-47.
29. **Carpenter LL**, Friehs GM, Price LH. 2003. Cervical vagus nerve stimulation for treatment-resistant depression. *Neurosurg Clin N Am* 14(2):275-82.

30. Greenberg BD, Price LH, Rauch SL, Friehs G, Noren G, Malone D, **Carpenter LL**, Rezai AR, Rasmussen SA. 2003. Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues. *Neurosurg Clin N Am* 14(2):199-212.
31. Marek GJ, **Carpenter LL**, McDougle CJ, Price LH. 2003. Synergistic action of 5-HT_{2A} antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. *Neuropsychopharmacology* 28(2):402-12.
32. Mello AA, Mello MF, **Carpenter LL**, Price LH. 2003. Update on stress and depression: the role of the hypothalamic-pituitary-adrenal (HPA) axis. *Rev Bras Psiquiatr* 25(4):231-8.
33. **Carpenter LL**, Henger GR, Malison RT, Tyrka AR, Price LH. 2004. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. *J Affect Disord* 79(1-3):285-9.
34. **Carpenter LL**, Moreno FA, Kling MA, Anderson GM, Regenold WT, Labiner DM, Price LH. 2004. Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients. *Biol Psychiatry* 56(6):418-26.
35. **Carpenter LL**, Schechter JM, Sinischalchi J, Leon Z, Price LH. 2004. A case series describing orlistat use in patients on psychotropic medications. *Med Health R I* 87(12):375-7.
36. **Carpenter LL**, Tyrka AR, McDougle CJ, Malison RT, Owens MJ, Nemeroff CB, Price LH. 2004. Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects. *Neuropsychopharmacology* 29(4):777-84.
37. Tyrka AR, **Carpenter LL**, McDougle CJ, Kirwin PD, Owens MJ, Nemeroff CB, Strong DR, Price LH. 2004. Increased cerebrospinal fluid corticotropin-releasing factor concentrations during tryptophan depletion in healthy adults. *Biol Psychiatry* 56(7):531-4.
38. **Carpenter LL**, Milosavljevic N, Schechter JM, Tyrka AR, Price LH. 2005. Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. *J Clin Psychiatry* 66(10):1234-8.
39. **Carpenter LL**, Schechter JM, Underwood JA, Tyrka AR, Price LH. 2005. Service expectations and clinical characteristics of patients receiving psychiatric emergency services. *Psychiatr Serv* 56(6):743-5.
40. Garriock HA, Allen JJ, Delgado P, Nahaz Z, Kling MA, **Carpenter L**, Burke M, Burke W, Schwartz T, Marangell LB, Husain M, Erickson RP, Moreno FA. 2005. Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. *Mol Psychiatry* 10(11):976-7.
41. George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, Howland R, Kling MA, Moreno F, Rittberg B, Dunner D, Schwartz T, **Carpenter L**, Burke M, Ninan P, Goodnick P. 2005. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. *Biol Psychiatry* 58(5):364-73.
42. Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, **Carpenter L**, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ. 2005. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. *Biol Psychiatry* 58(5):355-63.

43. **Carpenter LL**. 2006. Neurostimulation in resistant depression. *J Psychopharmacol* 20(3 Suppl):35-40.
44. **Carpenter LL**, Friehs GM, Tyrka AR, Rasmussen S, Price LH, Greenberg BD. 2006. Vagus nerve stimulation and deep brain stimulation for treatment resistant depression. *Med Health R I* 89(4):137, 140-1.
45. **Carpenter LL**, Schechter JM, Tyrka AR, Mello AF, Mello MF, Haggarty R, Price LH. 2006. Open-label tiagabine monotherapy for major depressive disorder with anxiety. *J Clin Psychiatry* 67(1):66-71.
46. Debattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, **Carpenter LL**, Alva G. Mifepristone versus Placebo in the Treatment of Psychosis in Patients with Psychotic Major Depression. *Biol Psychiatry* **60**(12): 1343-9.
47. Friehs GM, Ojakangas C, **Carpenter LL**, Greenberg B, Chou KL. 2006. Surgical aspects of deep brain stimulation. *Med Health R I* 89(4):134-6.
48. Garriock HA, Delgado P, Kling MA, **Carpenter LL**, Burke M, Burke WJ, Schwartz T, Marangell LB, Husain M, Erickson RP, Moreno FA. 2006. Number of risk genotypes is a risk factor for major depressive disorder: a case control study. *Behav Brain Funct* 2:24.
49. Geraciotti TD, Jr.* , **Carpenter LL***, Owens MJ, Baker DG, Ekhtor NN, Horn PS, Strawn JR, Sanacora G, Kinkead B, Price LH, Nemeroff CB. 2006. Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. *Am J Psychiatry* 163(4):637-43 *Co-first authors).
50. Tyrka AR, **Carpenter LL**, Carvalho JP, Price LH. 2006. Biomarkers in the human stress system: do they signal risk for depression? *Med Health R I* 89(5):180-2.
51. Tyrka AR, Mello AF, Mello MF, Gagne GG, Grover KE, Anderson GM, Price LH, **Carpenter LL**. 2006. Temperament and hypothalamic-pituitary-adrenal axis function in healthy adults. *Psychoneuroendocrinology* 31(9):1036-45.
52. Tyrka AR, Price LH, Mello MF, Mello AF, **Carpenter LL**. 2006. Psychotic major depression: a benefit-risk assessment of treatment options. *Drug Saf* 29(6):491-508.
53. Wier LM, Tavares SB, Tyrka AR, Price LH, **Carpenter LL**. 2006. Levetiracetam-induced depression in a healthy adult. *J Clin Psychiatry* 67(7):1159-60.
54. **Carpenter LL**, Carvalho JP, Tyrka AR, Wier LM, Mello AF, Mello MF, Anderson GM, Wilkinson CW, Price LH. 2007. Decreased adrenocorticotropic hormone and cortisol responses to stress in healthy adults reporting significant childhood maltreatment. *Biol Psychiatry* 62(10):1080-7.
55. Grover KE, **Carpenter LL**, Price LH, Gagne GG, Mello AF, Mello MF, Tyrka AR. 2007. The relationship between childhood abuse and adult personality disorder symptoms. *J Personal Disord* 21(4):442-7.
56. Kelly MM, Tyrka AR, Price LH, **Carpenter LL**. 2007. Sex differences in the use of coping strategies: predictors of anxiety and depressive symptoms. *Depress Anxiety*.
57. Mello AF, Juruena MF, Pariante CM, Tyrka AR, Price LH, **Carpenter LL**, Del Porto JA. 2007. [Depression and stress: is there an endophenotype?]. *Rev Bras Psiquiatr* 29 Suppl 1:S13-8.

58. Park MC, Goldman MA, **Carpenter LL**, Price LH, Friehs GM. 2007. Vagus nerve stimulation for depression: rationale, anatomical and physiological basis of efficacy and future prospects. *Acta Neurochir Suppl* 97(Pt 2):407-16.
59. Tyrka AR, Wier LM, Anderson GM, Wilkinson CW, Price LH, **Carpenter LL**. 2007. Temperament and response to the Trier Social Stress Test. *Acta Psychiatr Scand* 115(5):395-402.
60. Abrantes AM, Strong DR, Lejuez CW, Kahler CW, **Carpenter LL**, Price LH, Niaura R, Brown RA. 2008. The role of negative affect in risk for early lapse among low distress tolerance smokers. *Addict Behav* 33(11):1394-401.
61. **Carpenter LL**, Bayat L, Moreno F, Kling MA, Price LH, Tyrka AR, Kinkead B, Owens MJ, Nemeroff CB. 2008. Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. *Psychiatry Res* 157(1-3):123-9.
62. Greenberg BD, Askland KD, **Carpenter LL**. 2008. The evolution of deep brain stimulation for neuropsychiatric disorders. *Front Biosci* 13:4638-48.
63. Kelly MM, Tyrka AR, Anderson GM, Price LH, **Carpenter LL**. 2008. Sex differences in emotional and physiological responses to the Trier Social Stress Test. *J Behav Ther Exp Psychiatry* 39(1):87-98.
64. Philip NS, **Carpenter LL**, Tyrka AR, Price LH. 2008. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. *J Psychiatr Pract* 14(1):34-44.
65. Philip NS, Mello K, **Carpenter LL**, Tyrka AR, Price LH. 2008. Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. *Ann Clin Psychiatry* 20(1):15-20.
66. Rikhye K, Tyrka AR, Kelly MM, Gagne GG, Jr., Mello AF, Mello MF, Price LH, **Carpenter LL**. 2008. Interplay between childhood maltreatment, parental bonding, and gender effects: Impact on quality of life. *Child Abuse Negl* 32(1):19-34.
67. Tyrka AR, Wier L, Price LH, Ross N, Anderson GM, Wilkinson CW, **Carpenter LL**. 2008. Childhood parental loss and adult hypothalamic-pituitary-adrenal function. *Biol Psychiatry* 63(12):1147-54.
68. Tyrka AR, Wier L, Price LH, Ross NS, **Carpenter LL**. 2008. Childhood parental loss and adult psychopathology: effects of loss characteristics and contextual factors. *Int J Psychiatry Med* 38(3):329-44.
69. Tyrka AR, Wier LM, Price LH, Rikhye K, Ross NS, Anderson GM, Wilkinson CW, **Carpenter LL**. 2008. Cortisol and ACTH responses to the Dex/CRH Test: Influence of temperament. *Horm Behav*.
70. Brown RA, Lejuez CW, Strong DR, Kahler CW, Zvolensky MJ, **Carpenter LL**, Niaura R, Price LH. 2009. A prospective examination of distress tolerance and early smoking lapse in adult self-quitters. *Nicotine Tob Res* 11(5):493-502.
71. **Carpenter LL**, Ross NS, Tyrka AR, Anderson GM, Kelly M, Price LH. 2009. Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. *Psychoneuroendocrinology* 34(8):1208-13.

72. **Carpenter LL**, Tyrka AR, Ross NS, Khoury L, Anderson GM, Price LH. 2009. Effect of childhood emotional abuse and age on cortisol responsivity in adulthood. *Biol Psychiatry* 66(1):69-75.
73. Malone DA, Jr., Dougherty DD, Rezai AR, **Carpenter LL**, Friehs GM, Eskandar EN, Rauch SL, Rasmussen SA, Machado AG, Kubu CS, Tyrka AR, Price LH, Stypulkowski PH, Giftakis JE, Rise MT, Malloy PF, Salloway SP, Greenberg BD. 2009. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. *Biol Psychiatry* 65(4):267-75.
74. Mello MF, Faria AA, Mello AF, **Carpenter LL**, Tyrka AR, Price LH. 2009. [Childhood maltreatment and adult psychopathology: pathways to hypothalamic-pituitary-adrenal axis dysfunction]. *Rev Bras Psiquiatr* 31 Suppl 2:S41-8.
75. Philip NS, **Carpenter LL**, Tyrka AR, Whiteley LB, Price LH. 2009. Varenicline augmentation in depressed smokers: an 8-week, open-label study. *J Clin Psychiatry* 70(7): 1026-31.
76. Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson GM, **Carpenter LL**. 2009. Interaction of Childhood Maltreatment with the Corticotropin-Releasing Hormone Receptor Gene: Effects on Hypothalamic-Pituitary-Adrenal Axis Reactivity. *Biol Psychiatry* 66(7): 681-5.
77. Tyrka AR, Wyche MC, Kelly MM, Price LH, **Carpenter LL**. 2009. Childhood maltreatment and adult personality disorder symptoms: Influence of maltreatment type. *Psychiatry Res* 165(3):281-7.
78. Amin Z, Kanarek K, Krupitsky E, Walderhaug E, Ilomaki R, Blumberg H, Price LH, Bhagwagar Z, **Carpenter LL**, Tyrka AR, Magnusson A, Landro NI, Zvartau E, Gelernter J, Epperson CN, Rasanen P, Siironen J, Lappalainen J. 2010. A sequencing-based survey of functional APAF1 alleles in a large sample of individuals with affective illness and population controls. *Am J Med Genet B Neuropsychiatr Genet* 153B(1):332-5.
80. Philip NS, **Carpenter LL**, Tyrka AR, Price LH. 2010. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. *Expert Opin Pharmacother* 11(5):709-22.
81. Schoedl AF, Costa MC, Mari JJ, Mello MF, Tyrka AR, **Carpenter LL** and Price LH (2010). The clinical correlates of reported childhood sexual abuse: an association between age at trauma onset and severity of depression and PTSD in adults. *J Child Sex Abus* 19, 2, 156-70.
82. Tyrka AR, Price LH, Kao HT, Porton B, Marsella SA, **Carpenter LL**. 2010. Childhood maltreatment and telomere shortening: preliminary support for an effect of early stress on cellular aging. *Biol Psychiatry* 67(6):531-4.
83. Philip NS, **Carpenter LL**, Tyrka AR and Price LH (2010). Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature. *Psychopharmacology (Berl)* 212, 1, 1-12.
84. Yip AG and **Carpenter LL** (2010). Transcranial magnetic stimulation for medication-resistant depression. *J Clin Psychiatry* 71, 4, 502-3.
85. **Carpenter LL**, Gawuga CE, Tyrka AR, Lee JK, Anderson GM, Price LH (2010) Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. *Neuropsychopharmacology* 35: 2617-23
86. **Carpenter LL**, Shattuck TT, Tyrka AR, Geraciotti TD and Price LH (2010). Effect of childhood

- physical abuse on cortisol stress response. *Psychopharmacology (Berl)* **214**(1): 367-75.
87. **Carpenter LL**, Megna JL, Herrera-Rojas M, Siddiqui UA. When Medication Fails: Neurostimulation Therapies for Depression (2011). *Clinical Neuropsychiatry* 8, 1, 61-68.
 88. **Carpenter LL**, Tyrka AR, Lee JK, Tracy AP, Wilkinson CW, Price LH (2011). A placebo-controlled study of sertraline's effect on cortisol response to the dexamethasone/corticotropin-releasing hormone test in healthy adults." *Psychopharmacology (Berl)* **218**(2): 371-9.
 89. Nugent NR, Tyrka AR, **Carpenter LL**, Price LH. Gene-environment interactions: early life stress and risk for depressive and anxiety disorders. *Psychopharmacology (Berl)*. Mar 2011;214(1):175-196. Epub Date: 2011/01/13
 90. Cui D, Zhang H, Yang B-Z, Listman JB, Li D, Price LH, **Carpenter LL**, Tyrka AR, Anton RF, Kranzler HR, Gelernter J. 2011. Variation in NGFB Is Associated With Primary Affective Disorders in Women. *Am J Med Genet B Neuropsychiatr* 156:401–412. Epub Date: 2011/02/05
 91. Hsieh TH, Dhamne SC, Chen JJ, **Carpenter LL**, Anastasio EM, Pascual-Leone A, Rotenberg A. "Minimal heating of aneurysm clips during repetitive transcranial magnetic stimulation." *Clin Neurophysiol*. Epub Date: 2011/11/29
 92. Tyrka AR, Price LH, Marsit C, Walters OC, **Carpenter LL** (2012) "Childhood Adversity and Epigenetic Modulation of the Leukocyte Glucocorticoid Receptor: Preliminary Findings in Healthy Adults." *PLoS ONE* 7(1): e30148. doi:10.1371/journal.pone.0030148
 93. Tyrka AR, Walters OC, Price LH, Anderson GM, **Carpenter LL**. (2/22/12, accepted) "Altered Response to Neuroendocrine Challenge Linked to Indices of the Metabolic Syndrome in Healthy Adults." (2/22/12 accepted) *Hormone and Metabolic Research*

MANUSCRIPTS IN PREPARATION/SUBMITTED/IN PRESS

1. Aaronson SA, **Carpenter LL**, Conway C, Reimherr F, Lisanby HS, Schwartz T, Moreno F, Dunner D, Lesem M, Thompson P, Husain M, Vine C, Banov M, Bernstein L, Lehman R, Brannon G, Keepers G, O'Reardon J, Rudolph R, Bunker M. Vagus Nerve Stimulation Therapy Randomized to Different Amounts of Electrical Charge for Treatment-Resistant Depression: Acute and Chronic Effects. *J Clin Psychopharmacology*, in review 2012

BOOKS AND CHAPTERS

1. Kupfer DJ, **Carpenter LL**: Clinical evidence of comorbidity: a critique of treated samples and longitudinal studies. In Maser, JD and Cloninger, RC (Eds) *Comorbidity of Anxiety and Mood Disorders*, American Psychiatric Press, Inc., Washington, DC, 1990. (Chapt 13, pp. 231-238).
2. **Carpenter LL**, Leckman JF, McDougle CJ: Pharmacological approaches to the treatment of TS, OCD, and ADHD. In Leckman JF and Cohen DJ (Eds): *Tourette's Syndrome and Tic-related Obsessive Compulsive Disorder: Natural History, Genetics, Neurobiology and Treatment*. New York: Wiley-Liss, 1998; 340-367.

3. Price LH, **Carpenter LL**, Rasmussen SA: Drug combination strategies. In Amsterdam JD, Hornig M, Nierenberg AA (Eds): *Treatment-Resistant Mood Disorders*. Cambridge University Press, Cambridge, 2001;194-222.
4. **Carpenter, LL**: Defining Treatment Resistant Depression. Chapter in: *Novel Approaches to the Patient with Treatment-Resistant Depression*. CME Monograph from symposium proceedings June 16, 2001; pp. 3- 10.
5. De Mello MF, De Mello AAF, Juruena MF, **Carpenter LL**, Price LH: Psiconeuroendocrinologia no TEPT. In Mari J, Andreoli SB, Bressan RA, Feijó M (Eds), *Transtornos de Estresse Pós-Traumático – TEPT*. Barueri, Brasil: Editora Manole Ltda. Sao Paulo, Brazil, in press
6. Greenberg BD, Price LH, Rauch SL, Friehs G, Noren G, Malone D, **Carpenter LL**, Rezai AR, Rasmussen SA. Neurosurgery for intractable obsessive-compulsive disorder and depression: Critical issues. Chapter in: *Surgery for Psychiatric Disorders*, Rezai AR, Rasmussen SA, Greenberg BD (Eds). Neurosurgery Clinics of North America, Vol 14(2), WB Saunders, Philadelphia, pp 199-212, 2003.
7. **Carpenter LL**, Friehs G, Price LH. “Cervical vagus nerve stimulation for treatment resistant depression”. Chapter in: *Surgery for Psychiatric Disorders*. In the series: Neurosurgery Clinics of North America, WB Saunders, Philadelphia, pp 275-282, 2003.
8. Block DR, Yonkers KA, **Carpenter LL**. “Sertraline” Chapter 14 (pp307-320) in Schatzberg AF and Nemeroff CB (Eds). *APPI Textbook of Pharmacology*, Fourth Edition 2009. American Psychiatric Publishing, Inc, Arlington VA.
9. **Carpenter LL**, Wyche MC, Friehs GM, O’Reardon JP. “Electroconvulsive Therapy, Transcranial Magnetic Stimulation, and Vagus Nerve Stimulation for Depression”. Chapter 54 in *Neuromodulation: A Comprehensive Handbook*. Krames ES, Hunter P, Rezai AR (Eds). 2009 Academic Press, London.
10. **Carpenter LL**, Philip NS, O’Reardon J. “Advances in Neurostimulation for Depression: Electroconvulsive Therapy, Transcranial Magnetic Stimulation, Vagus Nerve Stimulation, and Deep Brain Stimulation”. Chapter 9 in *Depression: Treatment Strategies and Management, Second Edition*. TL. Schwartz and T. Peterson (Eds.) 2010, Informa Healthcare USA.
11. **Carpenter LL**, and Gawuga CE. Immune Consequences of Early Life Stress: Relationship to Chronic Pain Syndromes. Chapter in *Pain in Women: A Clinical Guide*. C Bernstein and A Bailey (Eds), in press Jan 2012, Springer, Inc., New York

OTHER NON-PEER REVIEWED PUBLICATIONS

1. **Carpenter LL**, McDougle CJ, Epperson CN Price LH: A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. *Drug Safety*, 1996; 15(2).
2. Price LH, **Carpenter LL**: The use of antigluocorticoids for treating depression. *Medscape Mental Health*, 1997; <http://www.medscape.com/>.
3. Epperson CN, **Carpenter LL**, North WG, McDougle CJ: Cerebrospinal fluid oxytocin levels in trichotillomania. *CNS Spectrums*, 1998; 52-55.

4. Price LH, Lemmond K, **Carpenter LL**: Refractory depression: Assessment and treatment. *Directions in Psychiatry*, 1999; 19:1-20.
5. **Carpenter LL**, Kalin NH, Keller MB, Krishnan KRR, Nemeroff CB: Atypical Depression: Overview and new developments. *CNS News Special Report*, CME Monograph May 2003.
6. Greenberg BD, Nahas Z, **Carpenter LL**, Current status of deep brain stimulation. *Primary Psychiatry*, 2005; 12(10): 59-64.
7. Block DR, Kelly MM, **Carpenter LL**, Generalized Anxiety Disorders Diagnostic and Treatment Issues. *Directions in Psychiatry*, 2006; 3 (26): 171-181.
8. Neurostimulation Therapies for Depression: Acute and Long-term Outcomes. Wyche MC, O'Reardon J, **Carpenter LL**. *Depression: Mind and Body* 2007; 3(3) 106-114.
9. Price LH, **Carpenter LL**, Tyrka AR. Lithium Augmentation for Refractory Depression: A Critical Reappraisal. *Primary Psychiatry* 2008; 15(1):35-42.